Skip to main content
Top
Published in: Journal of Translational Medicine 1/2014

Open Access 01-12-2014 | Research

Validation of a hemoglobin A1c model in patients with type 1 and type 2 diabetes and its use to go beyond the averaged relationship of hemoglobin A1c and mean glucose level

Authors: Piotr Ladyzynski, Piotr Foltynski, Marianna I Bak, Stanislawa Sabalinska, Janusz Krzymien, Jerzy Kawiak

Published in: Journal of Translational Medicine | Issue 1/2014

Login to get access

Abstract

Background

Glycated hemoglobin A1c (HbA1c) has been used as an index of glycemic control in the management, guidance, and clinical trials of diabetic patients for the past 35 years. The aim of this study was to validate the HbA1c model in patients with type 1 and type 2 diabetes and to use it to support interpretation of HbA1c in different clinical situations.

Methods

The HbA1c model was identified in 30 patients (15 with type 1 diabetes and 15 with type 2 diabetes) by estimating the overall glycation rate constant (k), based on results of continuous glucose monitoring. The model was validated by assessing its ability to predict HbA1c changes in cultures of erythrocytes in vitro and to reproduce results of the A1C-Derived Average Glucose (ADAG) study. The model was used to simulate the influence of different glucose profiles on HbA1c.

Results

The mean k was equal to 1.296 ± 0.216 × 10−9 l mmol−1 s−1 with no difference between type 1 and type 2 diabetes. The mean coefficient of variation of k was equal to 16.7%. The model predicted HbA1c levels in vitro with a mean absolute difference less than 0.3% (3.3 mmol/mol). It reproduced the linear relationship of HbA1c and mean glucose levels established in the ADAG study. The simulation experiments demonstrated that during periods of unstable glycemic control, glycemic profiles with the same mean glucose might result in much different HbA1c levels.

Conclusions

Patients with type 1 and type 2 diabetes are characterized by the same mean value of k, but there is considerable interindividual variation in the relationship of HbA1c and mean glucose level. Results suggest that reciprocal changes in glycation rate and the life span of erythrocytes exist in a wide range of HbA1c values. Thus, for an average patient with diabetes, no modifications of parameters of the glycation model are required to obtain meaningful HbA1c predictions. Interpreting HbA1c as a measure of the mean glucose is fully justified only in the case of stable glycemia. The model and more frequent tests of HbA1c might be used to decrease ambiguity of interpreting HbA1c in terms of glycemic control.
Appendix
Available only for authorised users
Literature
1.
go back to reference Nathan DM, The International Expert Committee: International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009, 32: 1327-1334. 10.2337/dc08-9025.CrossRef Nathan DM, The International Expert Committee: International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009, 32: 1327-1334. 10.2337/dc08-9025.CrossRef
2.
go back to reference Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ: Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008, 31: 1473-1478. 10.2337/dc08-0545.PubMedCentralCrossRefPubMed Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ: Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008, 31: 1473-1478. 10.2337/dc08-0545.PubMedCentralCrossRefPubMed
3.
go back to reference Beach KW: A theoretical model to predict the behavior of glycosylated hemoglobin levels. J Theor Biol. 1979, 81: 547-561. 10.1016/0022-5193(79)90052-3.CrossRefPubMed Beach KW: A theoretical model to predict the behavior of glycosylated hemoglobin levels. J Theor Biol. 1979, 81: 547-561. 10.1016/0022-5193(79)90052-3.CrossRefPubMed
4.
go back to reference Bunn HF, Haney DN, Kamin S, Gabbay KH, Gallop PM: The biosynthesis of human hemoglobin A1c. Slow glycation of hemoglobin in vivo. J Clin Invest. 1976, 57: 1652-1659. 10.1172/JCI108436.PubMedCentralCrossRefPubMed Bunn HF, Haney DN, Kamin S, Gabbay KH, Gallop PM: The biosynthesis of human hemoglobin A1c. Slow glycation of hemoglobin in vivo. J Clin Invest. 1976, 57: 1652-1659. 10.1172/JCI108436.PubMedCentralCrossRefPubMed
5.
go back to reference Graf RJ, Halter JB, Porte D: Glycosylated hemoglobin in normal subjects and subjects with maturityonset diabetes. Evidence for a saturable system in man. Diabetes. 1978, 27: 834-839. 10.2337/diab.27.8.834.CrossRefPubMed Graf RJ, Halter JB, Porte D: Glycosylated hemoglobin in normal subjects and subjects with maturityonset diabetes. Evidence for a saturable system in man. Diabetes. 1978, 27: 834-839. 10.2337/diab.27.8.834.CrossRefPubMed
6.
go back to reference Higgins PJ, Bunn HF: Kinetic analysis of the nonenzymatic glycosylation of hemoglobin. J Biol Chem. 1981, 256: 5204-5208.PubMed Higgins PJ, Bunn HF: Kinetic analysis of the nonenzymatic glycosylation of hemoglobin. J Biol Chem. 1981, 256: 5204-5208.PubMed
7.
go back to reference Ladyzynski P, Wojcicki JM, Bak M, Sabalinska S, Kawiak J, Foltynski P, Krzymien J, Karnafel W: Validation of hemoglobin glycation models using glycemia monitoring in vivo and culturing of erythrocytes in vitro. Ann Biomed Eng. 2008, 36: 1188-1202. 10.1007/s10439-008-9508-x.CrossRefPubMed Ladyzynski P, Wojcicki JM, Bak M, Sabalinska S, Kawiak J, Foltynski P, Krzymien J, Karnafel W: Validation of hemoglobin glycation models using glycemia monitoring in vivo and culturing of erythrocytes in vitro. Ann Biomed Eng. 2008, 36: 1188-1202. 10.1007/s10439-008-9508-x.CrossRefPubMed
8.
go back to reference Mortensen HB, Christophersen C: Glucosylation of human haemoglobin A in red blood cells studied in vitro. Kinetics of the formation and dissociation of haemoglobin A1c. Clin Chim Acta. 1983, 134: 317-326. 10.1016/0009-8981(83)90370-4.CrossRefPubMed Mortensen HB, Christophersen C: Glucosylation of human haemoglobin A in red blood cells studied in vitro. Kinetics of the formation and dissociation of haemoglobin A1c. Clin Chim Acta. 1983, 134: 317-326. 10.1016/0009-8981(83)90370-4.CrossRefPubMed
9.
go back to reference Kovatchev BP, Flacke F, Sieber J, Breton MD: Accuracy and robustness of dynamical tracking of average glycemia (A1c) to provide real-time estimation of hemoglobin A1c using routine self-monitored blood glucose data. Diabetes Technol Ther. 2014, 16: 303-309. 10.1089/dia.2013.0224.PubMedCentralCrossRefPubMed Kovatchev BP, Flacke F, Sieber J, Breton MD: Accuracy and robustness of dynamical tracking of average glycemia (A1c) to provide real-time estimation of hemoglobin A1c using routine self-monitored blood glucose data. Diabetes Technol Ther. 2014, 16: 303-309. 10.1089/dia.2013.0224.PubMedCentralCrossRefPubMed
10.
go back to reference Osterman-Golkar SM, Vesper HW: Assessment of the relationship between glucose and A1c using kinetic modeling. J Diabetes Complicat. 2006, 20: 285-294. 10.1016/j.jdiacomp.2005.07.009.CrossRefPubMed Osterman-Golkar SM, Vesper HW: Assessment of the relationship between glucose and A1c using kinetic modeling. J Diabetes Complicat. 2006, 20: 285-294. 10.1016/j.jdiacomp.2005.07.009.CrossRefPubMed
11.
go back to reference Tahara Y, Shima K: The response of GHb to stepwise plasma glucose change over time in diabetic patients. Diabetes Care. 1993, 16: 1313-1314. 10.2337/diacare.16.9.1313.CrossRefPubMed Tahara Y, Shima K: The response of GHb to stepwise plasma glucose change over time in diabetic patients. Diabetes Care. 1993, 16: 1313-1314. 10.2337/diacare.16.9.1313.CrossRefPubMed
12.
go back to reference Ladyzynski P, Wojcicki JM, Bak MI, Sabalinska S, Kawiak J, Foltynski P, Krzymien J, Karnafel W: Hemoglobin glycation rate constant in non-diabetic individuals. Ann Biomed Eng. 2011, 39: 2721-2734. 10.1007/s10439-011-0366-6.CrossRefPubMed Ladyzynski P, Wojcicki JM, Bak MI, Sabalinska S, Kawiak J, Foltynski P, Krzymien J, Karnafel W: Hemoglobin glycation rate constant in non-diabetic individuals. Ann Biomed Eng. 2011, 39: 2721-2734. 10.1007/s10439-011-0366-6.CrossRefPubMed
13.
go back to reference Cohen M, Boyle E, Delaney C, Shaw J: A comparison of blood glucose meters in Australia. Diabetes Res Clin Pract. 2006, 71: 113-118. 10.1016/j.diabres.2005.05.013.CrossRefPubMed Cohen M, Boyle E, Delaney C, Shaw J: A comparison of blood glucose meters in Australia. Diabetes Res Clin Pract. 2006, 71: 113-118. 10.1016/j.diabres.2005.05.013.CrossRefPubMed
14.
go back to reference D’Orazio P, Burnett RW, Fogh-Andersen N, Jacobs E, Kuwa K, Kulpmann WR, Larsson L, Lewenstam A, Maas AHJ, Mager G, Naskalski JW, Okorodudu AO, International Federation of Clinical Chemistry and Laboratory Medicine Scientific Division, Working Group on Selective Electrodes and Point-of-Care Testing (IFCC-SD-WG-SEPOCT): Approved IFCC recommendation on reporting results for blood glucose. Clin Chem Lab Med. 2006, 44: 1486-1490.PubMed D’Orazio P, Burnett RW, Fogh-Andersen N, Jacobs E, Kuwa K, Kulpmann WR, Larsson L, Lewenstam A, Maas AHJ, Mager G, Naskalski JW, Okorodudu AO, International Federation of Clinical Chemistry and Laboratory Medicine Scientific Division, Working Group on Selective Electrodes and Point-of-Care Testing (IFCC-SD-WG-SEPOCT): Approved IFCC recommendation on reporting results for blood glucose. Clin Chem Lab Med. 2006, 44: 1486-1490.PubMed
15.
go back to reference The Diabetes Research in Children Network (DirectNet) Study Group: The accuracy of the Guardian® RT continuous glucose monitor in children with type 1 diabetes. Diabetes Technol Ther. 2008, 10: 266-272. 10.1089/dia.2007.0279.CrossRef The Diabetes Research in Children Network (DirectNet) Study Group: The accuracy of the Guardian® RT continuous glucose monitor in children with type 1 diabetes. Diabetes Technol Ther. 2008, 10: 266-272. 10.1089/dia.2007.0279.CrossRef
16.
go back to reference Hoelzel W, Weykamp C, Jeppsson JO, Miedema K, Barr JR, Goodall I, Hoshino T, John WG, Kobold U, Little R, Mosca A, Mauri P, Paroni R, Susanto F, Takei I, Thienpont L, Umemoto M, Wiedmeyer HM, IFCC Working Group on HbA1c Standardization: IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem. 2004, 50: 166-174. 10.1373/clinchem.2003.024802.CrossRefPubMed Hoelzel W, Weykamp C, Jeppsson JO, Miedema K, Barr JR, Goodall I, Hoshino T, John WG, Kobold U, Little R, Mosca A, Mauri P, Paroni R, Susanto F, Takei I, Thienpont L, Umemoto M, Wiedmeyer HM, IFCC Working Group on HbA1c Standardization: IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem. 2004, 50: 166-174. 10.1373/clinchem.2003.024802.CrossRefPubMed
17.
go back to reference Zhang Y, Neelamegham S: Cell counter, blood. Encyclopedia of Medical Devices and Instrumentation. Edited by: Webster JG. 2006, John Wiley & Sons, New York, 81-90. Zhang Y, Neelamegham S: Cell counter, blood. Encyclopedia of Medical Devices and Instrumentation. Edited by: Webster JG. 2006, John Wiley & Sons, New York, 81-90.
18.
go back to reference Cohen RM, Franco RS, Khera PK, Smith EP, Lindsell CJ, Ciraolo PJ, Palascak MB, Joiner CH: Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c. Blood. 2008, 112: 4284-4291. 10.1182/blood-2008-04-154112.PubMedCentralCrossRefPubMed Cohen RM, Franco RS, Khera PK, Smith EP, Lindsell CJ, Ciraolo PJ, Palascak MB, Joiner CH: Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c. Blood. 2008, 112: 4284-4291. 10.1182/blood-2008-04-154112.PubMedCentralCrossRefPubMed
19.
go back to reference Lunn D, Spiegelhalter D, Thomas A, Best N: The BUGS project: evolution, critique and future directions (with discussion). Stat Med. 2009, 28: 3049-3082. 10.1002/sim.3680.CrossRefPubMed Lunn D, Spiegelhalter D, Thomas A, Best N: The BUGS project: evolution, critique and future directions (with discussion). Stat Med. 2009, 28: 3049-3082. 10.1002/sim.3680.CrossRefPubMed
20.
go back to reference Lehmann ED, Deutsch T, Carson ER, Sonksen PH: AIDA: an interactive diabetes advisor. Comput Meth Programs Biomed. 1994, 41: 183-203. 10.1016/0169-2607(94)90054-X.CrossRef Lehmann ED, Deutsch T, Carson ER, Sonksen PH: AIDA: an interactive diabetes advisor. Comput Meth Programs Biomed. 1994, 41: 183-203. 10.1016/0169-2607(94)90054-X.CrossRef
21.
go back to reference Nathan DM, Turgeon H, Regan S: Relationship between glycated haemoglobin levels and mean glucose levels over time. Diabetologia. 2007, 50: 2239-2244. 10.1007/s00125-007-0803-0.CrossRefPubMed Nathan DM, Turgeon H, Regan S: Relationship between glycated haemoglobin levels and mean glucose levels over time. Diabetologia. 2007, 50: 2239-2244. 10.1007/s00125-007-0803-0.CrossRefPubMed
22.
go back to reference Borg R, Kuenen JC, Carstensen B, Zheng H, Nathan DM, Heine RJ, Nerup J, Borch-Johnsen K, Witte DR, on behalf of the ADAG Study Group: Associations between features of glucose exposure and A1C. The A1C-Derived Average Glucose (ADAG) Study. Diabetes. 2010, 59: 1585-1590. 10.2337/db09-1774.PubMedCentralCrossRefPubMed Borg R, Kuenen JC, Carstensen B, Zheng H, Nathan DM, Heine RJ, Nerup J, Borch-Johnsen K, Witte DR, on behalf of the ADAG Study Group: Associations between features of glucose exposure and A1C. The A1C-Derived Average Glucose (ADAG) Study. Diabetes. 2010, 59: 1585-1590. 10.2337/db09-1774.PubMedCentralCrossRefPubMed
23.
go back to reference McCarter RJ, Hempe JM, Chalew SA: Mean blood glucose and biological variation have greater influence on HbA1c levels than glucose instability. An analysis of data from the Diabetes Control and Complications Trial. Diabetes Care. 2006, 9: 352-355. 10.2337/diacare.29.02.06.dc05-1594.CrossRef McCarter RJ, Hempe JM, Chalew SA: Mean blood glucose and biological variation have greater influence on HbA1c levels than glucose instability. An analysis of data from the Diabetes Control and Complications Trial. Diabetes Care. 2006, 9: 352-355. 10.2337/diacare.29.02.06.dc05-1594.CrossRef
24.
go back to reference Furne JK, Springfield JR, Ho SB, Levitt MD: Simplification of the end-alveolar carbon monoxide technique to assess erythrocyte survival. J Lab Clin Med. 2003, 142: 2-57. 10.1016/S0022-2143(03)00086-6.CrossRef Furne JK, Springfield JR, Ho SB, Levitt MD: Simplification of the end-alveolar carbon monoxide technique to assess erythrocyte survival. J Lab Clin Med. 2003, 142: 2-57. 10.1016/S0022-2143(03)00086-6.CrossRef
25.
go back to reference Virtue MA, Furne JK, Nuttall FQ, Levitt MD: Relationship between GHb concentration and erythrocyte survival determined from breath carbon monoxide concentration. Diabetes Care. 2004, 27: 931-935. 10.2337/diacare.27.4.931.CrossRefPubMed Virtue MA, Furne JK, Nuttall FQ, Levitt MD: Relationship between GHb concentration and erythrocyte survival determined from breath carbon monoxide concentration. Diabetes Care. 2004, 27: 931-935. 10.2337/diacare.27.4.931.CrossRefPubMed
26.
go back to reference Selvaraj N, Bobby Z, Sathiyapriya V: Effect of lipid peroxides and antioxidants on glycation of hemoglobin: an in vitro study on human erythrocytes. Clin Chim Acta. 2006, 366: 190-195. 10.1016/j.cca.2005.10.002.CrossRefPubMed Selvaraj N, Bobby Z, Sathiyapriya V: Effect of lipid peroxides and antioxidants on glycation of hemoglobin: an in vitro study on human erythrocytes. Clin Chim Acta. 2006, 366: 190-195. 10.1016/j.cca.2005.10.002.CrossRefPubMed
27.
go back to reference Peterson CM, Jones RL, Koenig RJ, Melvin ET, Lehrman ML: Reversible hematologic sequelae of diabetes mellitus. Ann Intern Med. 1977, 86: 425-429. 10.7326/0003-4819-86-4-425.CrossRefPubMed Peterson CM, Jones RL, Koenig RJ, Melvin ET, Lehrman ML: Reversible hematologic sequelae of diabetes mellitus. Ann Intern Med. 1977, 86: 425-429. 10.7326/0003-4819-86-4-425.CrossRefPubMed
28.
go back to reference Hempe JM, Gomez R, McCarter RJ, Chalew SA: High and low hemoglobin glycation phenotypes in type 1 diabetes: a challenge for interpretation of glycemic control. J Diabetes Complicat. 2002, 16: 313-320. 10.1016/S1056-8727(01)00227-6.CrossRefPubMed Hempe JM, Gomez R, McCarter RJ, Chalew SA: High and low hemoglobin glycation phenotypes in type 1 diabetes: a challenge for interpretation of glycemic control. J Diabetes Complicat. 2002, 16: 313-320. 10.1016/S1056-8727(01)00227-6.CrossRefPubMed
29.
go back to reference Gould BJ, Davie SJ, Yudkin SJ: Investigation of the mechanism underlying the variability of glycated haemoglobin in non-diabetic subjects not related to glycaemia. Clin Chim Acta. 1997, 260: 49-64. 10.1016/S0009-8981(96)06508-4.CrossRefPubMed Gould BJ, Davie SJ, Yudkin SJ: Investigation of the mechanism underlying the variability of glycated haemoglobin in non-diabetic subjects not related to glycaemia. Clin Chim Acta. 1997, 260: 49-64. 10.1016/S0009-8981(96)06508-4.CrossRefPubMed
30.
go back to reference Nathan DM, Singer DE, Hurxthal K, Goodson JD: The clinical information value of the glycosylated hemoglobin assay. N Engl J Med. 1984, 310: 341-346. 10.1056/NEJM198402093100602.CrossRefPubMed Nathan DM, Singer DE, Hurxthal K, Goodson JD: The clinical information value of the glycosylated hemoglobin assay. N Engl J Med. 1984, 310: 341-346. 10.1056/NEJM198402093100602.CrossRefPubMed
31.
go back to reference Sayinalp S, Sozen T, Usman A, Dundar S: Investigation of the effect of poorly controlled diabetes mellitus on erythrocyte life. J Diabetes Complicat. 1995, 9: 190-193. 10.1016/1056-8727(94)00041-L.CrossRefPubMed Sayinalp S, Sozen T, Usman A, Dundar S: Investigation of the effect of poorly controlled diabetes mellitus on erythrocyte life. J Diabetes Complicat. 1995, 9: 190-193. 10.1016/1056-8727(94)00041-L.CrossRefPubMed
32.
go back to reference Lledó-García R, Mazer NA, Karlsson MO: A semi-mechanistic model of the relationship between average glucose and HbA1c in healthy and diabetic subjects. J Pharmacokinet Pharmacodyn. 2013, 40: 129-142. 10.1007/s10928-012-9289-6.CrossRefPubMed Lledó-García R, Mazer NA, Karlsson MO: A semi-mechanistic model of the relationship between average glucose and HbA1c in healthy and diabetic subjects. J Pharmacokinet Pharmacodyn. 2013, 40: 129-142. 10.1007/s10928-012-9289-6.CrossRefPubMed
Metadata
Title
Validation of a hemoglobin A1c model in patients with type 1 and type 2 diabetes and its use to go beyond the averaged relationship of hemoglobin A1c and mean glucose level
Authors
Piotr Ladyzynski
Piotr Foltynski
Marianna I Bak
Stanislawa Sabalinska
Janusz Krzymien
Jerzy Kawiak
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2014
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-014-0328-5

Other articles of this Issue 1/2014

Journal of Translational Medicine 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.